MDM2 and breast carcinoma: In detail, archazolid inhibition of V-ATPase abrogates tumor metastasis via repression of endocytic activation [28], leads to impaired cathepsin B activation in vivo [30], modulates anoikis resistance and metastasis of cancer cells [31], overcomes trastuzumab resistance of breast cancers [32], blocks iron metabolism and thereby mediates therapeutic effects in breast cancers [33], and plays a role in tumor sensitizing in the context of the MDM2 antagonist nutlin-3a [34].